Summary
31 / 100 · Bulios Score
What speaks for it
- Revenue grew by 22% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
- It missed profit estimates 8 times in the last 8 quarters.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 24% a year over 5 years. Over the last 3 years it grew by 22% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $34.6M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $23.5 is 157% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Biologics and Drug Delivery Revenue 58%
- Biologics and Drug Delivery - Disposable Products 23%
- Capital Equipment and Software Revenue 9.5%
- Capital Equipment and Software - Systems and Software Products 5.2%
- Capital Equipment and Software - Services 4.3%
By region
The company reports no revenue by region.
Biologics and Drug Delivery Revenue brings in 58% of revenue.
Segments in detail